Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Through international collaboration, researchers at KAIST have revealed that RNA editing plays a crucial role in regulating neuroinflammation, a key pathology of Parkinson's disease. The paper is ...

Through international collaboration, researchers at KAIST have revealed that RNA editing plays a crucial role in regulating neuroinflammation, a key pathology of Parkinson's disease. KAIST ...

Recent research from the Korea Advanced Institute of Science and Technology (KAIST) reveals that RNA editing plays a role in modulating neuroinflammation, a critical factor in the disease's ...

rAIR-100 family of RNA editing research candidates demonstrated >50% RNA editing and restores wild-type AAT (M-AAT) protein levels above 30 µM with subcutaneous GalNAc delivery RESTORE+ platform ...

ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...

SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a ...

Rznomics Logo (PRNewsfoto/Rznomics Inc.) The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage ...

The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved ...